1. Home
  2. GNLX vs NYXH Comparison

GNLX vs NYXH Comparison

Compare GNLX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.86

Market Cap

113.6M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.29

Market Cap

126.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
NYXH
Founded
2001
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.6M
126.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GNLX
NYXH
Price
$2.86
$1.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$17.25
$9.33
AVG Volume (30 Days)
147.3K
286.7K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
N/A
EPS
N/A
N/A
Revenue
$8,000.00
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.29
$1.27
52 Week High
$8.54
$8.59

Technical Indicators

Market Signals
Indicator
GNLX
NYXH
Relative Strength Index (RSI) 47.05 18.33
Support Level $2.51 N/A
Resistance Level $2.97 $5.02
Average True Range (ATR) 0.14 0.17
MACD -0.02 -0.18
Stochastic Oscillator 4.65 1.68

Price Performance

Historical Comparison
GNLX
NYXH

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: